کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2020016 1069087 2007 10 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی زیست شیمی
پیش نمایش صفحه اول مقاله
Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids
چکیده انگلیسی

Inflammatory eicosanoids generated by the 5-lipoxygenase (5-LO) pathway of arachidonic acid metabolism are now known to have at least 6 receptors: OXE, which recognizes 5-HETE and 5-oxo-ETE; a putative receptor recognizing a potent 5-oxo-ETE metabolite, FOG7; the LTB4 receptors, BLT1 and BLT2; the cysteinyl leukotriene receptors, CysLT1 and CysLT2, which recognize leukotrienes LTC4, LTD4, LTE4 and LTF4. The 5-LO pathway is activated in many diseases and invokes inflammatory responses not affected by glucocorticoids, but therapy with selective BLT1 or CysLT1 antagonists in asthma has met with variable success. Studies show that 5-LO pathway eicosanoids are not primary mediators in all cases of asthma, but may be especially important in severe persistent asthma, aspirin- and exercise-induced asthma, allergic rhinitis, COPD, idiopathic pulmonary fibrosis, atherosclerosis, atopic dermatitis, acne and ischemia-related organ injury. These disorders appear to involve multiple 5-LO pathway eicosanoids and receptor subtypes, suggesting that inhibition of the pathway at the level of 5-LO may be necessary for maximal efficacy.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Prostaglandins & Other Lipid Mediators - Volume 83, Issue 3, May 2007, Pages 188–197
نویسندگان
, ,